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Abstract: Levobetaxolol is a cardioselective β-blocker that has been demonstrated to reduce 
intraocular pressure in patients affected with primary open-angle glaucoma and ocular hyper-
tension. Levobetaxolol may be an effective neuroprotectant because of its great capacity to 
block sodium and calcium inﬂ  ux, which might confer a neuroprotective activity. Experimental 
and clinical studies have demonstrated the effects of levobetaxolol on ocular hemodynamics 
and visual ﬁ  eld, and the pharmacologic differences between β-blockers currently used for 
the treatment of elevated IOP have become of more than academic interest since a number of 
studies have shown improvements to various extents. Unlike the initially manufactured 0.5% 
ophthalmic solution, levobetaxolol is suspended in a different delivery vehicle in levobetaxolol 
ophthalmic suspension, to increase the ocular tolerance and allow a similarity of effect with a 
2-fold reduced concentration (0.25%).
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Introduction
Levobetaxolol hydrochloride was introduced in the early 1980s as the ﬁ  rst cardioselec-
tive β1-adrenergic antagonist for the treatment of elevated intraocular pressure (IOP) 
(Berrospi and Leibowitz 1982).
Levobetaxolol is a single active isomer of betaxolol, a cardioselective β1-adrenergic 
receptor-blocking agent (betaxolol is a racemic mixture of D- and the active L-iso-
mers).
Since racemic betaxolol and other β-adrenergic antagonists have been shown to 
reduce IOP by a reduction of aqueous production as demonstrated by tonography and 
aqueous ﬂ  uorophotometry, it is assumed that levobetaxolol has a similar mechanism 
of action (Reiss and Brubaker 1983). Betaxolol, by having a greater afﬁ  nity for car-
diac (β1) than pulmonary receptors (β2), has been demonstrated to offer a reduced 
potential for pulmonary side effects, particularly in patients with pulmonary diseases 
(Weinreb et al 1988).
Several clinical studies have demonstrated the IOP lowering effect of the drug, in 
patients affected with primary open-angle glaucoma (POAG) and ocular hypertension 
(OHT) (Radius 1983; Caldwell et al 1984; Feghali and Kaufman 1985).
β-blockers can act as a neuroprotectant by reducing sodium inﬂ  ux into cells, and 
can also protect insulted neurones by reducing inﬂ  ux of calcium. Levobetaxolol may be 
an effective neuroprotectant because of its great capacity to block sodium and calcium 
inﬂ  ux, which might confer a neuroprotective activity (Hoste and Sys 1998).
Experimental and clinical studies have demonstrated the effects of levobetaxolol 
on ocular hemodynamics and visual ﬁ  elds, and the pharmacology differences between 
β-blockers currently used for the treatment of elevated IOP have become of more than Clinical Ophthalmology 2007:1(2) 94
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academic interest since a number of studies have shown 
improvements to various extents (Drance 1998, 1999; Turacli 
et al 1998; Harris et al 1995, 2000).
Unlike the initially manufactured 0.5% ophthalmic 
solution, levobetaxolol is suspended in a different delivery 
vehicle in levobetaxolol ophthalmic suspension, to increase 
the ocular tolerance and allow a similarity of effect with a 
2-fold reduced concentration (0.25%). The cationic exchange 
resin in which levobetaxolol is suspended provides micro-
scopic beads 5 microns in diameter, and residence time in 
the cul-de-sac is increased with the addition of a poly-acrylic 
polymer (Weinreb and Jani 1992; Yarangümeli ad Kural 
2004). It has been demonstrated that levobetaxolol ophthal-
mic suspension has similar efﬁ  cacy in reducing the IOP in 
POAG and OHT patients when compared with betaxolol 
solution (Weinreb et al 1990).
The present paper provides a brief review of the lit-




In comparisons between non-cardioselective β-blockers in 
reactive airway subjects, levobetaxolol was demonstrated to 
have less effect on pulmonary function (FEV1 and forced vital 
capacity [FVC]) (Schoene et al 1984), by having a greater 
afﬁ  nity for cardiac than pulmonary receptors.
The cardiovascular effects of levobetaxolol were com-
pared in double-masked, crossover studies with timolol 
maleate ophthalmic solution 0.5%. Levobetaxolol was shown 
during exercise to have signiﬁ  cantly less effect on heart rate 
and systolic blood pressure than timolol maleate (Phan et al 
1991; Yamada et al 2001).
Betaxolol, a racemic mixture of D and the active 
L-isomers, is commercially available in two forms: 0.5% oph-
thalmic solution, and the 0.25% ophthalmic suspension.
IOP reduction
β-adrenergic receptors are present in the ciliary epithelium-
process, choroid, retina, iris, and longitudinal and circular 
ciliary muscles, and at a lower percentage in the lens and 
cornea (Sharif et al 2001). They are also found in the tra-
becular meshwork (Yarangümeli and Kural 2004). Aqueous 
humor production is mediated by the non-pigmented ciliary 
epithelial cells of the ciliary process (Okisaka et al 1974).
A rise in cAMP causes an increase in aqueous formation 
mediated by β-agonist activity (Neufeld et al 1972; Townsend 
and Brubaker 1980; Sears 1984). Aqueous humor outﬂ  ow 
is increased by adrenergic stimulation relaxing (cAMP 
stimulation) trabecular meshwork (Neufeld et al 1975; 
Neufeld 1978; Wiederholt 1998).
Epinephrine and isoproterenol enhance aqueous humor 
outﬂ  ow, reducing cell area and increasing intercellular space 
in trabecular meshwork and Schlemm’s canal endothelial 
cells through a β-stimulation (Crider and Sharif 2002).
In non-pigmented ciliary epithelial cells, levobetaxolol 
was more potent than dextrobetaxolol or racemic betaxolol 
at inhibiting isoproterenol-stimulated cAMP production 
(Nathanson 1988; Crider and Sharif 2002).
Experimental data on the inhibition of adenylyl cyclase 
activity in non-pigmented ciliary epithelial cells and trabecu-
lar meshwork cells demonstrate that β2-receptors predomi-
nate in ciliary body and trabecular meshwork (Nathanson 
1981; Coca-Prados and Wax 1986; Wax and Molinoff 1987; 
Friedman et al 1999; Crider and Sharif 2002).
Levobetaxolol would therefore be expected to be more 
potent in decreasing aqueous humor production than dextro-
betaxolol, which is supported by the fact that levobetaxolol is 
more potent in decreasing IOP than dextrobetaxolol. Levo-
betaxolol was 89-fold β1-selective relative to its potency at 
β2-receptors in functional assays using isolated animal tissues 
(guinea pig atria for β1-receptors, guinea pig tracheal rings 
for β2-receptors). In this study levobetaxolol demonstrated 
higher β1- and β2-receptor afﬁ  nities and functional potencies, 
and a higher β1-selectivity than dextrobetaxolol. Levobunolol 
and (l)-timolol, while having high afﬁ  nities and potencies 
at β1- and β2-receptors, exhibited insigniﬁ  cant β-receptor 
selectivity (2- and 3-fold β1-selective) (Sharif et al 2001). 
Levobetaxolol exhibited a higher afﬁ  nity at cloned human 
β1-(ki = 0.76 nM) than at β2-(ki = 32.6 nM) receptors, while 
dextrobetaxolol was much weaker at both receptors (43-fold 
β1-selectivity for levobetaxolol) at recombinant human β1-
and β2-receptors (Sharif et al 2001).
In an animal in vivo model, levobetaxolol was more potent 
than dextrobetaxolol in reducing IOP by a maximum of 25.9 ± 
3.2%, whereas the same dose of dextrobetaxolol reduced IOP 
by 15.5 ± 3.6%; the efﬁ  cacy of racemic betaxolol was very 
similar to that of levobetaxolol (Sharif et al 2001).
Topical treatment with betaxolol has been shown to re-
duce IOP signiﬁ  cantly in normal subjects, and in POAG and 
OHT patients in placebo-controlled studies (Radius 1983; 
Caldwell et al 1984; Feghali and Kaufman 1985), as well 
as in masked comparisons with timolol (Berry et al 1984; 
Allen et al 1986; Stewart et al 1986), and levobunolol (Long 
et al 1988). All these drugs have been found comparable 
with regard to their efﬁ  cacy in lowering IOP; however, the Clinical Ophthalmology 2007:1(2) 95
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decrease of IOP has been found to be signiﬁ  cantly smaller 
with betaxolol compared with timolol or levobunolol in a 
number of clinical trials (Radius 1983; Caldwell et al 1984; 
Berry et al 1984; Feghali and Kaufman 1985; Stewart et al 
1986; Allen et al 1986; Long et al 1988; Messmer et al 1991; 
Kaiser et al 1994; Yarangümeli and Kural 2004).
In two controlled clinical studies, in which a total of 356 
patients were dosed for 3 months, betaxolol ophthalmic sus-
pension produced clinically relevant reductions in IOP at all 
follow-up visits. At 8 AM after night-time dosing (trough), 
IOP was reduced from baseline by approximately 4–5 mmHg 
(16%–21%). At 10 AM, 2 hours after dosing (peak), IOP was 
reduced from baseline by approximately 5–6 mmHg (20% 
to 23%) (Weinreb et al 1990).
Adverse effects
Although betaxolol is pharmacodynamically selective for 
β1-adrenoreceptors, the extent of β1-receptor occupancy of 
topically applied betaxolol in the systemic circulation has 
been found to be less than that of the three non-selective 
blockers: timolol, levobunolol, and carteolol (Phan et al 
1991; Yamada et al 2001); this indicates a lesser systemic 
β1-blocking activity of betaxolol, associated with negligible 
systemic β2-blockade, which provides a better safety proﬁ  le 
for the drug.
Systemic absorption allows topical β-adrenergic blockers 
to cause adverse effects on pulmonary, cardiac and central 
nervous system (Van Buskirk 1980; Le Jeunne et al 1990). 
Non-selective β-blockers commonly used in glaucoma 
therapy cause bronchopulmonary constriction and depress 
cardiovascular performance (Le Jeunne et al 1990; Sharif 
et al 2001) while selective β-blockers such as betaxolol 
and levobetaxolol do not have this side effect. In the heart 
β1-adrenoceptors predominate, while in the lung and trachea 
there is a predominance of β2-adrenoceptors (Rugg et al 1978; 
Henry et al 1990; Satoh et al 1993).
Sharif and Xu (2004) determined the relative afﬁ  nities 
and selectivities of timolol, levobunolol, levobetaxolol 
racemic betaxolol, and other β-blockers at the native β1- and 
β2-adrenoceptors in guinea pig heart and lung using radio-
ligand binding, demonstrating that racemic betaxolol and 
levobetaxolol exhibited a higher afﬁ  nity and greater selectiv-
ity for the β-adrenoceptors than the destro enantiomer.
Betaxolol and levobetaxolol possessed a 193- to 233-fold 
selectivity for β1-receptors, and levobunolol a 140-fold selec-
tivity for β2-receptors; timolol was essentially non-selective.
Any ocular hypotensive treatment that can reduce blood 
pressure and heart rate can act as an additional risk factor in 
the development and progression of POAG (Quaranta et al 
2006). Most of the studies have shown the lack of effects 
of betaxolol on the cardiovascular system (Berrospi and 
Leibowitz 1982; Caldwell et al 1984; Feghali and Kaufman 
1985; Berry et al 1984; Long et al 1988).
Due to the very low binding affinity to pulmonary 
β2-receptors, betaxolol is generally well tolerated and does 
not produce signiﬁ  cant modiﬁ  cation of pulmonary function 
tests in glaucoma patients with asthma and chronic obstruc-
tive pulmonary disease (Weinreb et al 1988; Van Buskirk et al 
1986; Goldberg and Goldberg 1995; Schoene et al 1984).
However, it should be remembered that some pulmo-
nary complications have also been reported associated with 
betaxolol treatment (Harris et al 1986; Roholt 1987).
Effects on ocular blood ﬂ  ow
Betaxolol can improve ocular perfusion, increasing blood 
velocity in retinal and epipapillary capillaries (Arend et al 
1998); can increase end-diastolic velocity and decrease resis-
tance index trough (determined by color Doppler imaging), 
a vasorelaxant effect in retrobulbar vessels (posterior ciliary 
arteries, central retinal artery) (Harris et al 1995; Steigerwalt 
et al 2001); and can increase retinal blood ﬂ  ow as a long-term 
effect after drug application (Yoshida et al 1998).
Kulkarni and De Santis (2001) demonstrated the 
vasorelaxant effects of DL-betaxolol, D-betaxolol, and 
L-betaxolol on bovine retinal vessels. The compounds had 
the same vasodilatatory effect without statistically signiﬁ  cant 
differences.
Levobetaxolol would have the same action on blood ocu-
lar vessels as racemic betaxolol (unrelated to stereoselective 
β-blocking activity), perhaps involving an interaction with 
calcium channels.
Calcium-sodium channel blocking 
activity and neuroprotection
β1-blockers can act as neuroprotectants by reducing sodium 
inﬂ  ux into cells acting as; they can also protect insulted 
neurones by reducing calcium inﬂ  ux. Levobetaxolol may be 
an effective neuroprotectant because of its great capacity to 
block sodium and calcium inﬂ  ux (Melena et al 1999; Chidlow 
et al 2000; Osborne et al 2004).
An ischemic-like insult to the optic nerve causes 
a decline of ATP and failure of the NA+/K+-ATPase, 
which leads to an accumulation of intra-axonal sodium. 
This rise in intracellular sodium leads to reversal of the 
NA+/Ca2+ exchanger, which imports damaging quantities 
of calcium into the intracellular compartment. Elevated Clinical Ophthalmology 2007:1(2) 96
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extracellular concentrations of glutamate cause excito-
toxic injury, leading to an excessive stimulation of gan-
glion cell glutamate receptors and an entry of Ca+ and 
Na+ ions. This rise in ion concentration will activate the open-
ing of voltage-gated channels and cause a greater elevation of 
Na+ and Ca+ concentration, a trigger for a cascade of events 
that lead to cell death.
Glutamate receptor antagonist or the use of sodium 
or calcium channel blockers can protect the ganglion 
cell bodies from excitotoxic injury. Glutamate an-
tagonists would not be effective at the axonal lev-
el, so to protect the entire ganglion cell in glaucoma, 
the ideal way would be that of using a glutamate recep-
tor antagonist together with a sodium-channel blocker or 
a substance that prevents the reversal of sodium/calcium 
exchanger (Osborne et al 2004).
Betaxolol can inhibit Na+ inﬂ  ux modulating the gating 
mechanism of the Na+ channel, not interfering with ion con-
ductance directly. Betaxolol inhibited veratridine-stimulated 
(lipophilic toxin that causes a persistent activation of the Na+ 
channel) Na+ inﬂ  ux into rat cortical synaptosomes without 
statistically signiﬁ  cant differences between the effects of le-
vobetaxolol and that of racemic betaxolol, so that it is possible 
to conclude that stereoselectivity is not relevant to the afﬁ  n-
ity of betaxolol for the neurotoxin site 2 of the Na+ channel. 
Atenolol, timolol, levobunolol, and cateolol were signiﬁ  cantly 
less active than betaxolol (Chidlow et al 2000).
It has been demonstrated that betaxolol has an afﬁ  nity 
for the L-type voltage-gated calcium channel and is able 
to counteract the N-methyl-D-aspartate-induced inﬂ  ux of 
radioactive calcium into the retina (Melena et al 2001).
Osborne et al (2004), using an ischemia/reperfusion 
model recording ﬂ  ash electroretinograms after a reperfusion 
period in ischemic rat retinas, showed that levobetaxolol is 
more effective than timolol as a neuroprotectant.
Levobetaxolol demonstrates a higher afﬁ  nity than dex-
trobetaxolol against L-type Ca+ channels, but no signiﬁ  cant 
afﬁ  nity at N-type Ca+ channels. Levobetaxolol is able to 
counteract the NMDA-induced inﬂ  ux of radioactive calcium 
into rat retinas (Sharif et al 2001; Melena et al 2001). This 
L-type Ca+ channel blocking activity is clinically relevant 
because an increase in optic nerve head blood ﬂ  ow and 
beneﬁ  cial effects on visual ﬁ  elds in glaucoma patients are 
associated with various Ca2+-antagonists (Cellini et al 1997; 
Koseki et al 1999).
Levobetaxolol could act as a neuroprotectant both for 
the axon (in which voltage-sensitive sodium channels are re-
sponsible for generation and propagation of action potentials) 
(Chidlow et al 2000), and for the cell body and dendrites, 
reducing the toxic inﬂ  ux of calcium glutamate-mediated 
(Osborne et al 2004) blocking of both calcium and sodium 
channels.
Furthermore, it has been shown that systemic dosed levo-
betaxolol exerts a neuroprotective action in photic-induced 
retinal damage. This molecule can upregulate endogenous 
b-ﬁ  broblast growth factor and ciliary neurotrophic factor-
mRNA (two growth factors implicated in the protection of 
photoreceptor cells). Levobetaxolol was able to protect the 
retinal function (tested with an electroretinogram), and to 
prevent changes in retinal morphology after photic-induced 
retinopathy (Agarwal et al 2002).
Conclusions
Betaxolol is a well-documented drug in glaucoma therapy, 
and its efﬁ  cacy in lowering the IOP is comparable with that 
of the non-selective β-blockers.
Betaxolol offers a superior safety proﬁ  le, especially in 
patients with cardio-pulmonary diseases. Due to the calcium 
channel-blocker activity, betaxolol has all the characteristics 
for improving ocular perfusion and protecting retinal gan-
glion cells from loss related to glaucoma.
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